Clinical analysis of aerosol inhalation of salbutamol combined with non-invasive mechanical ventilation for treating acute exacerbation of chronic obstructive pulmonary disease

doi:10.3877/cma.j.issn.1674-6902.2020.04.009

Abstract

Abstract:

Objective

To observe the effect of aerosol inhalation of salbutamol combined with non-invasive mechanical ventilation on the bronchodilation response and gas exchange parameters in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Methods

Eighty patients with AECOPD were selected from our hospital and randomized into two groups with the number table method, with 40 cases in each group. The control group was treated with non-invasive mechanical ventilation, and the experimental group was treated with aerosol inhalation of salbutamol combined with non-invasive mechanical ventilation. The lung function parameters [the forced vital capacity (FVC), the forced expiratory volume in one second (FEV₁), and FEV₁/FVC], the gas exchange parameters [the minute ventilation volume (VE), the tidal volume (VT), and the respiratory rate (RR)], the bronchial dilation test response [the change in FVC (ΔFVC) and its improvement rate, and the change in FEV₁ (ΔFEV₁) and its improvement rate], the disappearance time of the symptoms and signs, and the adverse reactions were compared between the two groups.

Results

After treatment, the FVC, FEV₁, FEV₁/FVC, VE, VT and RR in the experimental group were significantly higher than those of the control group (P<0.05). There was no significant difference in the ΔFEV₁ or its improvement rate between the two groups (P>0.05). The ΔFVC and its improvement rate in the experimental group were significantly lower than those of the control group (P<0.05). The disappearance time of cough, dyspnea, cyanosis and lung rales in the experimental group was significantly shorter than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

Conclusion

Aerosol inhalation of salbutamol combined with non-invasive mechanical ventilation can effectively improve the lung function and gas exchange parameters in the patients with AECOPD, reduce the bronchodilation response, promote the recovery of the symptoms and signs, and has a high safety.

Key words: Salbutamol, Non-invasive mechanical ventilation, Chronic obstructive pulmonary disease, Bronchodilation response, Gas exchange parameters

Qing Yang, Yingjie Hu. Clinical analysis of aerosol inhalation of salbutamol combined with non-invasive mechanical ventilation for treating acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(04): 475-478.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.04.009

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I04/475

Figures/Tables 4

References 25

1	任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2	Echevarria C, Steer J, Heslop-Marshall K, et al. The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPD[J]. Thorax, 2017, 72(8): 686-693.
3	Harrison SL, Janaudis-Ferreira T, Brooks D, et al. Self-Management Following an Acute Exacerbation of COPD[J]. Chest, 2015, 147(3): 646-661.
4	陈　平，李柳村，罗　红，等. 慢性阻塞性肺疾病急性加重期呼吸支持策略与方式选择[J]. 中华结核和呼吸杂志，2017, 40(12): 887-890.
5	王金荣，高　攀，郭淑芬，等. 慢性阻塞性肺疾病无创通气期间高浓度吸氧对二氧化碳分压的影响[J]. 中国呼吸与危重监护杂志，2016, 15(4): 329-332.
6	潘　宜，黄晓颖. 布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J]. 中国临床药理学杂志，2016, 32(15): 1347-1349.
7	杨　丽，金英姬，张亚明. 布地奈德联合沙丁胺醇治疗婴幼儿毛细支气管炎的临床观察[J]. 中国药房，2017, 28(20): 2817-2819.
8	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志，2013, 36(4): 255-264.
9	Glossop AJ, Esquinas AM. Using Noninvasive Ventilation in Ordinary Wards to Treat Acute Respiratory Failure：，But Where, When, and Whom to Treat？[J]. Crit Care Med, 2017, 45(2): e236.
10	Esquinas AM, Shah PS. Noninvasive mechanical ventilation and mechanical in-exsufflator: A definitive solid combination? Some key methodology considerations[J]. Pediatr Pulmonol, 2014, 49(10): 1043-1044.
11	武良权，杨　健，仝春冉，等. 序贯机械通气治疗慢性阻塞性肺疾病急性加重合并呼吸衰竭失败原因分析[J]. 中华结核和呼吸杂志，2018, 41(9): 714-717.
12	杨嘉雯，王宗强，王小华. 老年慢性阻塞性肺疾病急性加重患者有创机械通气撤机失败危险因素分析[J]. 中国呼吸与危重监护杂志，2015, 14(1): 13-16.
13	孙宇星，付文龙，袁小平，等. 硫酸镁和/或沙丁胺醇雾化吸入对哮喘患儿吸入乙酰胆碱激发后肺功能影响的随机对照研究[J]. 中国循证儿科杂志，2014, 9(1): 6-10.
14	马锦芳，郑劲平，曹照龙，等. 沙丁胺醇吸入粉雾剂与气雾剂治疗支气管哮喘的随机对照多中心研究[J]. 中国新药与临床杂志，2015, 34(2): 115-119.
15	韩　霜，何　锟，蔚冬冬，等. 雾化吸入布地奈德混合沙丁胺醇对单肺通气兔萎陷侧肺组织HIF-1α/VEGF信号通路的影响[J]. 中华麻醉学杂志，2019, 39(11): 1315-1318.
16	李　敏，汤　昱，赵二要，等. 雾化吸入沙丁胺醇混悬液治疗哮喘患儿的临床研究[J]. 中国临床药理学杂志，2017, 33(19): 1858-1861.
17	王　芳，张永建，陆娟英. 布地奈德、沙丁胺醇联合异丙托溴铵雾化吸入在慢性阻塞性肺疾病急性加重期中应用的临床观察[J]. 中国药房，2014, 25(44): 4150-4153.
18	柳知含，邸兴伟，钟　磊，等. 自适应分钟通气+智能触发通气模式在轻中度急性呼吸窘迫综合征患者中的临床应用[J]. 中华危重病急救医学，2020, 32(1): 20-25.
19	张学莉，黄　英，赵　艳，等. 重组人干扰素α2b雾化治疗毛细支气管炎近期疗效与远期预后评价[J]. 中国实用儿科杂志，2016, 31(9): 690-693.
20	王　娜. 慢性阻塞性肺疾病伴呼吸衰竭患者雾化吸人的疗效[J]. 中国老年学杂志，2014, 24(2): 3434-3435.
21	王　芳，姜晨宇，罗旭平，等. 深吸气量在鉴别慢性阻塞性肺疾病和支气管哮喘-慢性阻塞性肺疾病重叠中的应用价值研究[J]．中国全科医学，2019, 22(33): 4053-4057.
22	高稚婷，高晓华，张锋英，等. 支气管舒张试验结果不同的慢性阻塞性肺疾病患者的临床特点[J]. 中国呼吸与危重监护杂志，2015, 14(3): 264-268.
23	柴晶晶，朱华栋，于学忠，等. 慢性阻塞性肺疾病评估测试对COPD急性加重的有效性评估[J]. 中国急救医学，2017, 37(2): 158-163.
24	潘明鸣，张洪胜，孙铁英. 老年男性支气管哮喘-慢性阻塞性肺疾病重叠综合征患者肺功能特征分析[J]. 中华老年医学杂志，2017, 36(2): 146-150.
25	杜舒婷，邢　彬，丁连明，等. 呼吸操及肌力训练联合支气管舒张药治疗中重度慢性阻塞性肺疾病患者的疗效观察[J]. 中华物理医学与康复杂志，2014, 36(2): 115-119.

组　别		例数	FVC(L)		FEV₁(L)		FEV₁/FVC
组　别		例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验组		42	1.87±0.26	2.39±0.27^a	0.62±0.10	1.72±0.28^a	0.48±0.06	0.73±0.12^a
对照组		38	1.85±0.24	2.07±0.35^a	0.61±0.09	1.15±0.16^a	0.50±0.07	0.61±0.10^a
	t值		0.365	4.578	0.470	11.179	1.372	4.859
	P值		0.716	<0.001	0.640	<0.001	0.174	<0.001

组　别		例数	FVC(L)		FEV₁(L)		FEV₁/FVC
组　别		例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验组		42	1.87±0.26	2.39±0.27^a	0.62±0.10	1.72±0.28^a	0.48±0.06	0.73±0.12^a
对照组		38	1.85±0.24	2.07±0.35^a	0.61±0.09	1.15±0.16^a	0.50±0.07	0.61±0.10^a
	t值		0.365	4.578	0.470	11.179	1.372	4.859
	P值		0.716	<0.001	0.640	<0.001	0.174	<0.001

组　别		例数	VE(L/min)		VT(L)		RR(次/min)
组　别		例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验组		42	11.29±1.86	16.07±2.38^a	0.61±0.10	1.42±0.24^a	14.63±2.05	22.78±4.16^a
对照组		38	11.31±1.87	14.75±2.31^a	0.64±0.11	1.03±0.18^a	14.85±2.10	19.93±3.24^a
	t值		0.048	2.517	1.276	8.222	0.474	3.418
	P值		0.962	0.014	0.206	<0.001	0.637	0.001

组　别		例数	VE(L/min)		VT(L)		RR(次/min)
组　别		例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
实验组		42	11.29±1.86	16.07±2.38^a	0.61±0.10	1.42±0.24^a	14.63±2.05	22.78±4.16^a
对照组		38	11.31±1.87	14.75±2.31^a	0.64±0.11	1.03±0.18^a	14.85±2.10	19.93±3.24^a
	t值		0.048	2.517	1.276	8.222	0.474	3.418
	P值		0.962	0.014	0.206	<0.001	0.637	0.001

组　别		例数	ΔFVC	FVC改善率	ΔFEV₁	FEV₁改善率
实验组		42	0.15±0.03	8(20.00)	0.15±0.03	10(25.00)
对照组		38	0.18±0.03	17(42.50)	0.14±0.02	12(30.00)
	t/χ²		4.472	4.713	1.754	0.251
	P值		<0.001	0.030	0.083	0.617

Please choose a citation manager

Content to export